Source comparison
Comparison: PT141 vs Melanotan II vs PDE5 Inhibitors
Bremelanotide (PT141/PT-141) CNS melanocortin agonist MC4R, MC1R (hypothalamus) 45–60 minutes 6–8 hours Approved (Vyleesi, 2019) Central arousal pathway; no vascular component; on-demand dosing Melanotan II Non-selective melanocortin agonist MC1R, MC3R, MC4R,
This comparison does not assign a generated winner or score.
- Bremelanotide (PT141/PT-141)
- CNS melanocortin agonist
- MC4R, MC1R (hypothalamus)
- 45–60 minutes
- 6–8 hours
- Approved (Vyleesi, 2019)
- Central arousal pathway; no vascular component; on-demand dosing
- Melanotan II
- Non-selective melanocortin agonist
- MC1R, MC3R, MC4R, MC5R
- 30–45 minutes
- 8–12 hours
- Not approved (research only)
- Causes hyperpigmentation; broader receptor binding; unregulated safety profile
- Sildenafil (Viagra)
- PDE5 inhibition
- PDE5 (vascular smooth muscle)
- 30–60 minutes
- 4–6 hours
- Approved (1998)
- Peripheral vasodilation; requires sexual stimulation; no CNS effect on desire
- Flibanserin (Addyi)
- Serotonin modulation
- 5-HT1A agonist, 5-HT2A antagonist
- Chronic (weeks)
- Continuous
- Approved (2015)
- Daily oral dosing; acts on serotonergic tone; alcohol contraindication